DSpace Repository

Systemic lupus erythematosus: A therapeutic challenge for the XXI century

Show simple item record

dc.contributor.author Ugarte Gil, Manuel Francisco
dc.contributor.author Alarcón, Graciela S.
dc.date.accessioned 2020-06-10T18:11:29Z
dc.date.available 2020-06-10T18:11:29Z
dc.date.issued 2014
dc.identifier.uri https://hdl.handle.net/20.500.12866/7953
dc.description.abstract Despite significant advances in our understanding of the pathogenesis of systemic lupus erythematosus (SLE), there are only a few drugs approved by the regulatory agencies across the world for the treatment of these patients; in fact, many of the compounds subjected to clinical trials have failed in achieving their primary endpoints. Current therapeutic options include antimalarials which should be used in all SLE patients unless they are strongly contraindicated, glucocorticoids which should be used at the lowest possible dose and for the shortest possible time, and immunosuppressive drugs which should be used judiciously, mainly in patients with severe organ involvements or receiving high doses of steroids to control their disease. Despite improvement on the survival of SLE patients, damage accrual has not varied over the last few decades, reflecting a gap between these therapeutic options and the expectations of these patients and their treating physicians. Biologic compounds can be used in some refractory cases. However, their cost is of great concern for both the patients and the health system. Cost is of special importance in low-income countries, because low-income SLE patients tend to experience a more severe disease having an overall worse prognosis which is compounded by their limited access to the health system. Although a treatment to target based on defined molecular pathways for specific disease subsets is appealing, this is not yet a reality. This review addressed current therapeutic options for SLE patients and the state of the art of investigational drugs targeting pathogenic pathways identified in these patients. en_US
dc.language.iso eng
dc.publisher Springer
dc.relation.ispartofseries Clinical Rheumatology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject abatacept en_US
dc.subject anifrolumab en_US
dc.subject antimalarial agent en_US
dc.subject Antimalarials en_US
dc.subject apremilast en_US
dc.subject atacicept en_US
dc.subject azathioprine en_US
dc.subject belimumab en_US
dc.subject biological product en_US
dc.subject blisibimod en_US
dc.subject cyclophosphamide en_US
dc.subject disease control en_US
dc.subject drug cost en_US
dc.subject drug development en_US
dc.subject Drug Discovery en_US
dc.subject epratuzumab en_US
dc.subject etanercept en_US
dc.subject glucocorticoid en_US
dc.subject health care en_US
dc.subject health care access en_US
dc.subject human en_US
dc.subject Humans en_US
dc.subject immunosuppressive agent en_US
dc.subject Immunosuppressive Agents en_US
dc.subject infliximab en_US
dc.subject leflunomide en_US
dc.subject lowest income group en_US
dc.subject lupus erythematosus nephritis en_US
dc.subject Lupus Erythematosus, Systemic en_US
dc.subject methotrexate en_US
dc.subject methylprednisolone en_US
dc.subject milatuzumab en_US
dc.subject mycophenolic acid 2 morpholinoethyl ester en_US
dc.subject ocrelizumab en_US
dc.subject palladium en_US
dc.subject physician en_US
dc.subject priority journal en_US
dc.subject prognosis en_US
dc.subject review en_US
dc.subject rituximab en_US
dc.subject rontalizumab en_US
dc.subject sifalimumab en_US
dc.subject silver en_US
dc.subject steroid en_US
dc.subject survival en_US
dc.subject systemic lupus erythematosus en_US
dc.subject Systemic lupus erythematosus en_US
dc.subject tabalumab en_US
dc.subject tacrolimus en_US
dc.subject time en_US
dc.subject Treatment en_US
dc.subject treatment failure en_US
dc.subject unindexed drug en_US
dc.title Systemic lupus erythematosus: A therapeutic challenge for the XXI century en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1007/s10067-014-2531-4
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.17
dc.relation.issn 1434-9949

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


My Account